What Emalex Biosciences does

Emalex Biosciences was a Chicago-based, clinical-stage biotechnology company founded in 2018 by Paragon Biosciences to develop treatments for central nervous system disorders. The company's singular focus was ecopipam, a first-in-class investigational selective dopamine D1 receptor antagonist positioned as a treatment for pediatric Tourette syndrome — a chronic neurodevelopmental disorder characterized by involuntary motor and vocal tics typically with onset between ages 5 and 10. The mechanism is differentiated from incumbent D2-targeting antipsychotics commonly used off-label for Tourette syndrome, with the goal of reducing metabolic side effects and tardive dyskinesia risk while delivering tic control. The intended end user is a narrow pediatric specialty population for whom no FDA-approved treatment has been introduced in more than a decade.

Ecopipam was advanced through a Phase 3 trial enrolling 216 participants across 77 sites, with results published in JAMA Neurology in May 2026 demonstrating a 50% reduction in relapse risk versus placebo (p = 0.0084). The asset received FDA Orphan Drug and Fast Track designations, a U.S. patent was issued for an orally disintegrating tablet formulation, and the FDA authorized an Expanded Access Program that enrolled approximately 200 patients. Emalex was a single-asset, pre-commercial biotech that raised roughly $320 million across three funding rounds between 2020 and 2022 from Bain Capital Life Sciences, Fidelity, Paragon Biosciences, Valor Equity Partners, and Horizon Technology Finance. The economic model was binary: licensing/royalty realization contingent on FDA approval and commercial launch, with Jefferies analysts projecting peak sales of up to $1 billion against a Tourette syndrome treatment market the Business Research Company sizes at $3.38 billion by 2030 (6.4% CAGR).

On June 10, 2026, Teva Pharmaceutical Industries completed its acquisition of Emalex for $700 million in cash at closing, with potential for an additional $200 million in commercial milestone payments plus net-sales-based royalties. An NDA submission to the U.S. FDA was filed in mid-2026, to be advanced under Teva's neuroscience franchise as part of its Pivot to Growth strategy. As an independent entity, Emalex had no product on market and no operating revenue; the go-to-market motion was regulatory-led rather than commercial, with distribution and physician-facing channels established only post-acquisition through Teva.

Name

Emalex Biosciences

Legal name

Emalex Biosciences

Website

https://emalexbiosciences.com

Company type

Private

Founded year

2020

Operating status

Acquired

Headcount range

51–100 employees

Short description

Emalex Biosciences was a Chicago-based clinical-stage biotech developing ecopipam, a first-in-class dopamine D1 receptor antagonist for pediatric Tourette syndrome. The single-asset company advanced ecopipam through Phase 3 trials and was acquired by Teva in June 2026 for $700 million upfront.

Ownership category

akta.pro rank

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Drug Development and Commercialization: Emalex operated as a clinical-stage biotech developing ecopipam through Phase 3 trials for pediatric Tourette syndrome. The company was acquired by Teva Pharmaceutical for $700 million upfront plus up to $200 million in commercial milestone payments and royalties, making it a pre-commercial stage company without independent revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Emalex Biosciences is a clinical-stage biopharmaceutical company developing ecopipam, a first-in-class selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. The company also developed an orally disintegrating tablet formulation of ecopipam (U.S. patent) and operated an FDA-authorized Expanded Access Program in the U.S. Prior to its June 2026 acquisition by Teva Pharmaceutical, the company's primary commercial pathway was an NDA submission supported by positive Phase 3 data published in JAMA Neurology.

Product overview

Emalex Biosciences was a single-asset biotechnology company focused on developing ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company advanced ecopipam through clinical development, completing Phase 3 trials that demonstrated statistically significant efficacy. Emalex also developed an orally disintegrating tablet formulation and established an Expanded Access Program. The company was acquired by Teva Pharmaceuticals in June 2026 for $700 million upfront plus up to $200 million in milestones.

Differentiator

Problem solved

Functional benefit

Products and services

• Ecopipam Ecopipam is a first-in-class selective dopamine D1 receptor antagonist investigational therapy for pediatric Tourette syndrome. It acts on D1 receptors rather than D2, offering fewer metabolic and neurological side effects than existing off-label antipsychotics. Phase 3 data showed a 50% reduction in relapse risk vs placebo with p=0.0084, and the compound has received FDA Orphan Drug and Fast Track designations.
• Ecopipam Orally Disintegrating Tablet An orally disintegrating tablet formulation of ecopipam protected by a U.S. patent, designed to enable pediatric patients who have difficulty swallowing standard tablets to receive the therapy. Emalex plans further development and clinical studies of the formulation.

Quantifiable outcome

• Continued use of ecopipam cuts risk of relapse by 50% compared to placebo (Phase 3, JAMA Neurology, May 2026)
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Teva Pharmaceutical IndustriescoreStrategic or Co-development Partner · 10 June 2026Teva Pharmaceutical Industries completed the acquisition of Emalex Biosciences on June 10, 2026, paying $700 million at closing with potential for up to $200 million in additional commercial milestone payments and net-sales-based royalties. The acquisition adds ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome with Phase 3 data published in JAMA Neurology and FDA Orphan Drug and Fast Track designations, to Teva's late-stage neuroscience pipeline. The transaction advances Teva's Pivot to Growth strategy.
• Paragon BiosciencescoreStrategic or Co-development PartnerEmalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. Paragon supported Emalex in advancing ecopipam through clinical development and compiling the NDA submission for pediatric Tourette syndrome. Paragon closed the sale of Emalex to Teva for $700 million in cash plus up to $200 million in commercial milestone payments and net-sales-based royalties.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Acadia Pharmaceuticals: Acadia Pharmaceuticals is a CNS-focused commercial-stage biotech with FDA-approved therapies for Parkinson's disease psychosis and Rett syndrome, sharing Emalex's specialization in CNS disorders with high unmet need and rare/orphan-like patient populations.
• Axsome Therapeutics: Axsome Therapeutics is a CNS-focused commercial biotech with FDA-approved Auvelity for major depressive disorder and migraine therapies, sharing Emalex's profile of advancing first-in-class CNS mechanisms through clinical development to commercial launch.
• Karuna Therapeutics: Karuna Therapeutics developed KarXT (xanomeline-trospium), a first-in-class muscarinic agonist for schizophrenia approved by the FDA and acquired by Bristol Myers Squibb — a directly comparable CNS biotech that achieved a multi-billion-dollar exit on a novel-mechanism neuropsychiatric asset.
• Intra-Cellular Therapies: Intra-Cellular Therapies developed and commercializes Caplyta (lumateperone) for schizophrenia and bipolar depression, making it a directly comparable mid-cap CNS biotech with novel-mechanism assets targeting neuropsychiatric indications analogous to Emalex's ecopipam approach.
• Neumora Therapeutics: Neumora Therapeutics is a clinical-stage CNS biotech focused on neuropsychiatric and neurodegenerative disorders, pursuing novel mechanisms with backing from ARCH Venture Partners. Comparable to Emalex as a late-clinical-stage neuroscience developer targeting underserved brain disorders.
• Neurocrine Biosciences: Neurocrine Biosciences is a CNS-focused biotech with valbenazine (Ingrezza) approved for tardive dyskinesia and an active clinical program in Tourette syndrome. It is the most directly comparable late-stage CNS neuroscience developer and shares Emalex's focus on movement and neuropsychiatric disorders.
• BioXcel Therapeutics: BioXcel Therapeutics is a CNS and immuno-oncology biotech with FDA-approved Igalmi for agitation in schizophrenia and bipolar disorder, sharing Emalex's strategy of developing neuroscience assets for underserved neuropsychiatric symptoms in specialty patient populations.
• Praxis Precision Medicines: Praxis Precision Medicines is a clinical-stage CNS biotech focused on movement disorders and epilepsy, with programs analogous to Emalex's pediatric Tourette focus. Both pursue orphan and specialty neurology indications through targeted clinical development.
• Sage Therapeutics: Sage Therapeutics is a CNS-focused biotech with FDA-approved Zurzuvae (zuranolone) for postpartum depression, comparable to Emalex as a clinical-stage-to-commercial CNS developer pursuing novel mechanisms in underserved neuropsychiatric indications.

Broad incumbents

• Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is the acquirer of Emalex and a broad incumbent in neuroscience with established CNS commercial infrastructure globally. Post-acquisition it is the parent owner of ecopipam and competes with Emalex-as-prior-positioning through its broader neurology portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/emalex-biosciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emalex Biosciences